Selected research
Industry Research
Neuraminidase Inhibitor Industry Research Report 2026
Market perspective
The global Neuraminidase Inhibitor market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Neuraminidase Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Neuraminidase Inhibitor is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Neuraminidase Inhibitor is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Neuraminidase Inhibitor include GlaxoSmithKline, Gilead Sciences, F. Hoffman-La Roche, Daiichi Sankyo and BioCryst, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Neuraminidase Inhibitor market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Neuraminidase Inhibitor Market by Company
GlaxoSmithKline
Gilead Sciences
F. Hoffman-La Roche
Daiichi Sankyo
BioCryst
Neuraminidase Inhibitor Segment by Type
Oseltamivir
Laninamivir
Peramivir
Zanamivir
Neuraminidase Inhibitor Segment by Application
Hospital Pharmacies
Drug Stores
Retail Stores
Others
Neuraminidase Inhibitor Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuraminidase Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Neuraminidase Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuraminidase Inhibitor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Neuraminidase Inhibitor manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Neuraminidase Inhibitor by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Neuraminidase Inhibitor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oseltamivir
- Laninamivir
- Peramivir
- Zanamivir
Applications
- Hospital Pharmacies
- Drug Stores
- Retail Stores
- Others
Companies covered
- GlaxoSmithKline
- Gilead Sciences
- F. Hoffman-La Roche
- Daiichi Sankyo
- BioCryst
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Neuraminidase Inhibitor Market Size (2021-2032)
- 2.2.2 Global Neuraminidase Inhibitor Sales (2021-2032)
- 2.2.3 Global Neuraminidase Inhibitor Market Average Price (2021-2032)
- 2.3 Neuraminidase Inhibitor by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Oseltamivir
- 2.3.3 Laninamivir
- 2.3.4 Peramivir
- 2.3.5 Zanamivir
- 2.4 Neuraminidase Inhibitor by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital Pharmacies
- 2.4.3 Drug Stores
- 2.4.4 Retail Stores
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Neuraminidase Inhibitor Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Neuraminidase Inhibitor Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Neuraminidase Inhibitor Revenue of Manufacturers (2021-2026)
- 3.4 Global Neuraminidase Inhibitor Average Price by Manufacturers (2021-2026)
- 3.5 Global Neuraminidase Inhibitor Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Neuraminidase Inhibitor, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Neuraminidase Inhibitor, Product Type & Application
- 3.8 Global Manufacturers of Neuraminidase Inhibitor, Established Date
- 3.9 Global Neuraminidase Inhibitor Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 GlaxoSmithKline
- 4.1.1 GlaxoSmithKline Company Information
- 4.1.2 GlaxoSmithKline Business Overview
- 4.1.3 GlaxoSmithKline Neuraminidase Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 GlaxoSmithKline Neuraminidase Inhibitor Product Portfolio
- 4.1.5 GlaxoSmithKline Recent Developments
- 4.2 Gilead Sciences
- 4.2.1 Gilead Sciences Company Information
- 4.2.2 Gilead Sciences Business Overview
- 4.2.3 Gilead Sciences Neuraminidase Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Gilead Sciences Neuraminidase Inhibitor Product Portfolio
- 4.2.5 Gilead Sciences Recent Developments
- 4.3 F. Hoffman-La Roche
- 4.3.1 F. Hoffman-La Roche Company Information
- 4.3.2 F. Hoffman-La Roche Business Overview
- 4.3.3 F. Hoffman-La Roche Neuraminidase Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 F. Hoffman-La Roche Neuraminidase Inhibitor Product Portfolio
- 4.3.5 F. Hoffman-La Roche Recent Developments
- 4.4 Daiichi Sankyo
- 4.4.1 Daiichi Sankyo Company Information
- 4.4.2 Daiichi Sankyo Business Overview
- 4.4.3 Daiichi Sankyo Neuraminidase Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Daiichi Sankyo Neuraminidase Inhibitor Product Portfolio
- 4.4.5 Daiichi Sankyo Recent Developments
- 4.5 BioCryst
- 4.5.1 BioCryst Company Information
- 4.5.2 BioCryst Business Overview
- 4.5.3 BioCryst Neuraminidase Inhibitor Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 BioCryst Neuraminidase Inhibitor Product Portfolio
- 4.5.5 BioCryst Recent Developments
5 Global Neuraminidase Inhibitor Market Scenario by Region
- 5.1 Global Neuraminidase Inhibitor Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Neuraminidase Inhibitor Sales by Region: 2021-2032
- 5.2.1 Global Neuraminidase Inhibitor Sales by Region: 2021-2026
- 5.2.2 Global Neuraminidase Inhibitor Sales by Region: 2027-2032
- 5.3 Global Neuraminidase Inhibitor Revenue by Region: 2021-2032
- 5.3.1 Global Neuraminidase Inhibitor Revenue by Region: 2021-2026
- 5.3.2 Global Neuraminidase Inhibitor Revenue by Region: 2027-2032
- 5.4 North America Neuraminidase Inhibitor Market Facts & Figures by Country
- 5.4.1 North America Neuraminidase Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Neuraminidase Inhibitor Sales by Country (2021-2032)
- 5.4.3 North America Neuraminidase Inhibitor Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Neuraminidase Inhibitor Market Facts & Figures by Country
- 5.5.1 Europe Neuraminidase Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Neuraminidase Inhibitor Sales by Country (2021-2032)
- 5.5.3 Europe Neuraminidase Inhibitor Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Neuraminidase Inhibitor Market Facts & Figures by Country
- 5.6.1 Asia Pacific Neuraminidase Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Neuraminidase Inhibitor Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Neuraminidase Inhibitor Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Neuraminidase Inhibitor Market Facts & Figures by Country
- 5.7.1 South America Neuraminidase Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Neuraminidase Inhibitor Sales by Country (2021-2032)
- 5.7.3 South America Neuraminidase Inhibitor Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Neuraminidase Inhibitor Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Neuraminidase Inhibitor Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Neuraminidase Inhibitor Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Neuraminidase Inhibitor Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Neuraminidase Inhibitor Sales by Type (2021-2032)
- 6.1.1 Global Neuraminidase Inhibitor Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Neuraminidase Inhibitor Sales Market Share by Type (2021-2032)
- 6.2 Global Neuraminidase Inhibitor Revenue by Type (2021-2032)
- 6.2.1 Global Neuraminidase Inhibitor Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Neuraminidase Inhibitor Revenue Market Share by Type (2021-2032)
- 6.3 Global Neuraminidase Inhibitor Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Neuraminidase Inhibitor Sales by Application (2021-2032)
- 7.1.1 Global Neuraminidase Inhibitor Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Neuraminidase Inhibitor Sales Market Share by Application (2021-2032)
- 7.2 Global Neuraminidase Inhibitor Revenue by Application (2021-2032)
- 7.2.1 Global Neuraminidase Inhibitor Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Neuraminidase Inhibitor Revenue Market Share by Application (2021-2032)
- 7.3 Global Neuraminidase Inhibitor Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Neuraminidase Inhibitor Value Chain Analysis
- 8.1.1 Neuraminidase Inhibitor Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Neuraminidase Inhibitor Production Mode & Process
- 8.2 Neuraminidase Inhibitor Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Neuraminidase Inhibitor Distributors
- 8.2.3 Neuraminidase Inhibitor Customers
9 Global Neuraminidase Inhibitor Analyzing Market Dynamics
- 9.1 Neuraminidase Inhibitor Industry Trends
- 9.2 Neuraminidase Inhibitor Industry Drivers
- 9.3 Neuraminidase Inhibitor Industry Opportunities and Challenges
- 9.4 Neuraminidase Inhibitor Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst